share_log

BMO Capital Maintains Market Perform on CytomX Therapeutics, Raises Price Target to $3.59

Benzinga ·  May 9, 2024 22:54

BMO Capital analyst Etzer Darout maintains CytomX Therapeutics (NASDAQ:CTMX) with a Market Perform and raises the price target from $3.25 to $3.59.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment